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Abstract
Background: Primitive brain tumors are the leading cause of cancer-related death in children. Tumor cells with stem-like
properties (TSCs), thought to account for tumorigenesis and therapeutic resistance, have been isolated from high-grade
gliomas in adults. Whether TSCs are a common component of pediatric brain tumors and are of clinical relevance remains to
be determined.
Methodology/Principal Findings: Tumor cells with self-renewal properties were isolated with cell biology techniques from
a majority of 55 pediatric brain tumors samples, regardless of their histopathologies and grades of malignancy (57% of
embryonal tumors, 57% of low-grade gliomas and neuro-glial tumors, 70% of ependymomas, 91% of high-grade gliomas).
Most high-grade glioma-derived oncospheres (10/12) sustained long-term self-renewal akin to neural stem cells (.7 self-
renewals), whereas cells with limited renewing abilities akin to neural progenitors dominated in all other tumors. Regardless
of tumor entities, the young age group was associated with self-renewal properties akin to neural stem cells (P=0.05, chi-
square test). Survival analysis of the cohort showed an association between isolation of cells with long-term self-renewal
abilities and a higher patient mortality rate (P=0.013, log-rank test). Sampling of low- and high-grade glioma cultures
showed that self-renewing cells forming oncospheres shared a molecular profile comprising embryonic and neural stem cell
markers. Further characterization performed on subsets of high-grade gliomas and one low-grade glioma culture showed
combination of this profile with mesenchymal markers, the radio-chemoresistance of the cells and the formation of
aggressive tumors after intracerebral grafting.
Conclusions/Significance: In brain tumors affecting adult patients, TSCs have been isolated only from high-grade gliomas.
In contrast, our data show that tumor cells with stem cell-like or progenitor-like properties can be isolated from a wide
range of histological sub-types and grades of pediatric brain tumors. They suggest that cellular mechanisms fueling tumor
development differ between adult and pediatric brain tumors.
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Introduction
Primitive brain tumors are neoplasms of varied histopatholog-
ical appearance that affect both adults and children [1,2]. The
prognosis of their most malignant forms remains poor despite
development of combined therapeutic treatments. Research in
cell biology and gene expression studies have provided support
for the idea that tumor stem cells (TSCs), a subpopulation of
cancer cells that differ from the other cancerous components by
their properties similar to either neural progenitors or neural stem
cells, and their peculiar resistance to current therapeutics [3–5],
account for the origin, development and therapeutic resistance of
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terized only from a limited number of brain tumor types,
essentially glioblastomas in adults and medulloblastomas in adults
and children [6–13]. They form oncospheres in defined medium,
which self-renew. Two types of TSCs have been isolated: TSCs
that like neural stem cells have extended self-renewal properties,
and TSCs that like neural progenitors or transit amplifying cells
are endowed with a limited self-renewal capability. For example,
TSCs isolated from pediatric and adult medulloblastomas [8,9]
differ from their counterparts isolated from adult high-grade
gliomas by their limited self-renewal potential, which is closer to
that of neural progenitors than to that of neural stem cells
[7,12,14,15]. Coherently, studies of murine medulloblastomas
have shown that cerebellar progenitors are the cell of origin of
these high-grade embryonal tumors [16]. TSCs share also with
neural progenitors and/or neural stem cells several molecular
markers [6,8,9,17], and generate in vivo a phenocopy of the tumor
from which they derive [9,11,17]. Experimental demonstrations
that either mature glial cells having undergone a de-differenti-
ation process [18] or that neural stem cells or neural progenitors
[19,20] may behave as the cell of origin of brain tumors suggest
that most of these neoplasms could contain TSCs, regardless of
their cell of origin. Independent laboratories have reported
isolation of TSCs from a majority of adult high-grade brain
tumors they assayed, either glioblastomas or malignant glio-
neuronal tumors (MGNT) [6-11,13]. Data are less numerous in
children, and the different physiopathological properties exhib-
ited by pediatric and adult brain tumors [21–24] limit the
extrapolation of data obtained in one group of age to the other.
In children, tumor cells with neural progenitor-like features have
been isolated from medulloblastomas and ependymomas [25],
and TSCs have been well characterized from a few cases of low-
and high-grade gliomas [7,12].
To determine the extent to which TSCs are a general
component of primitive brain tumors, or are specific of certain
tumor types, we performed a comparative study using a large
sample of fifty-five pediatric brain tumors of various categories and
grades of malignancy. The current controversies surrounding the
criteria defining TSCs [11,26–31], and the limited amount of data
on TSCs from pediatric brain tumors led us to apply cell culture
paradigms that reveal the properties of tumor cells with no a priori
inference of the cell function from its surface markers [9,12].
Indeed, no consensus has been achieved regarding membrane
markers specific to adult glioma-derived TSCs, their expression
varying among tumor samples and/or depending on environmen-
tal signals [11,26–28]. We also paid special attention to the two
TSC properties consistently shown throughout the extensive
literature devoted to the subject, i.e. capacity of the cells to grow
under the form of oncospheres and to self-renew either in a limited
or extended manner.
Our data show that tumor cells with self-renewal properties and
markers of neural progenitors and neural stem cells can be isolated
from a majority of pediatric brain tumors regardless of their
histopathological subtypes and grades of malignancy.
Materials and Methods
Ethics statement
The biological study was approved by the Internal Review
Board of the Biological Resource Center of the Necker Sick
Children Hospital in Paris. Tumor samples were obtained after
signed informed consent from the parents of children who
underwent surgery at Necker hospital from February 2007 to
June 2009.
Sample collections and isolation of brain tumor cells
Tumor samples were cut into 1 mm
3 pieces and placed into
either RPMI buffer for immediate processing or into freezing
medium (90% serum, 10% DMSO) prior to being progressively
cooled to 280uC.
Cell dissociation was performed enzymatically [7,11] or
mechanically. All of the methods employed resulted in similar
cell survival rates (range, 27–95%). Fresh or frozen biopsies
yielded similar rates of viable cells. Cells were plated at 5610
4
cells/cm
2 in either house-made [11] or NSA-H medium (Stem
Cell, France) with 10 ng/ml FGF, 20 ng/ml EGF, and 1 mg/ml
Heparin [32]. Viable cell numbers varied from 2610
5 to 2610
7 in
relation to the sample size. The cells were further cultured until
appearance of floating cellular spheres. Half of the culture medium
was renewed each week. The ability of cells forming spheres to
generate novel spheres over successive passages was evaluated
through seeding the individual cells at low densities (10
4 cells/
cm
2), starting when the spheres reached a minimum 100 mm
diameter as described [32]. One self-renewal was scored when the
numbers of 100 mm diameter floating spheres counted under
phase contrast microscopy were at least two-fold more abundant
than in the previous passage. The reported limited self-renewal
capacity (#5) of tumor-initiating cells isolated from human
pediatric medulloblastomas [9,12], and the converse ability of
mouse and human neural stem cells to sustain at least seven self-
renewals [14,15] (see also supplementary information on human
fetal neural stem cells), led us to distinguish cells with a self-renewal
ability of two to seven doublings, from those with a self-renewal
ability greater than seven. Once the cultures stabilized, the spheres
were routinely dissociated once a week and plated at 10
6 cells/
75 cm
2/10 ml. Clonal properties were assessed by seeding in 96-
well plates at 1–2 cells/well or in methylcellulose containing
medium as previously described [14]. The characterization of
human fetal neural stem cells is provided in the supplementary
data and in Figure S1.
Molecular profiling
Flow cytometry analysis of cell surface antigens CD15 and
CD133 was performed as previously described [11]. Immunocy-
tochemical and immunohistochemical procedures and image
acquisition were performed as previously described [18,33]
(Table S1). Real-time quantitative RT-PCR (qPCR) was
performed as previously described [34], with each sample
normalized on the basis of its content in transcripts of the TATA
box-binding protein, TBP. Results of target gene expression are
presented as Ntarget values (Ntarget =2
Ct sample -C tTBP,C tc y c l e
threshold), which were subsequently further normalized such that
the mean of the cortectomies (CX) Ntarget values was 1. The
nucleotide sequences of primers for TBP and target genes are
available upon request.
CGH array, and mutation analyses of p53
The karyotype of the isolated cells was analyzed at the Agilent
Platform of the Cancer research institute of Lille (University of
Lille 2, IFR 114, France) using Agilent 4X180K human CGH
microarrays and by Integragen society (France) using human
cytoSNP-12 microarrays from Illumina. The microarray data
related to this paper have been submitted to the Array Express
data repository at the European Bioinformatics institute (http://
www.ebi.ac.uk/arrayexpress/) under the accession numbers E-
MEXP-2909 and E-MEXP-2910 and are MIAME compliant.
DNA and RNA were extracted from pediatric gliomas cultures
with DNAeasy and RNeasy Mini Kit (Qiagen, France). DNA
fragments were generated by reverse transcription (RT) of total
Tumor Stem-Like Cells in Pediatric Brain Tumors
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MLV Reverse Transcriptase (Promega, France). PCR was performed
by using 1 ml of the RT reaction and PlatinumH Taq DNA
Polymerase High Fidelity (Invitrogen, France). The primers were
designed to overlap TP53 exons 4/5 (
59CTGTGACTTGCACG-
TACTCC
39) and exons 8/9 (
59TTGGGCAGTGCTCGCTTA-
GT
39). The thermocycling conditions were 5 min at 94uC for
enzyme activation, followed by 35 cycles of 94uC for 30 sec, 60uC
for 1 min, 68uC for 1 min. The PCR products (568 bp length)
were purified and sequenced (Biofidal, France).
Grafts
Mechanically dissociated oncospheres (1–2 10
4 cells/ml PBS-
glucose buffer) were grafted within the right striatum of 6- to 7-
week-old male nude mice (Charles River, France) or 2-month-old
male NOD-SCID-ILR2
2/2 (NSG) mice (Jackson Laboratory, Bar
Harbor, Maine, USA) (1.5–2 ml/graft i.e. 1.5–4 10
4 cells/graft).
The in situ development of the oncospheres was analyzed as
previously described [18,33].
Response to genotoxic stress
Spheres were dissociated, seeded at 10
4 cells/100 ml/vial, and
cultured 24 hours prior to 5 Gy -radiation as previously described
[18]. Cells seeded at 2610
4 cells/100 ml/vial were treated with
500 mM temozolomide (Interchim, AM195, France) or its vehicle
DMSO. Cell viability was evaluated with the Cell Proliferation
Reagent WST-1 kit following the manufacturer’s instructions
(Roche, France).
Statistical analysis
Overall survival was calculated from the time of surgery to
death or time of last follow-up appointment for surviving patients.
Chi-square tests were performed to test the significance of clinical
differences between subtypes. Kaplan-Meier analyses were
performed for survival data using the log-rank test. The Cox
model was used to study prognostic factors on overall survival.
Univariate and multivariate analyses were performed for both the
whole series and after exclusion of the low-grade tumors. All P-
values were two sided, and P,0.05 was considered significant.
Analyses were performed using SPSS 16.0 for Windows.
Results
Tumor and patient characteristics
Tumors were classified following the WHO classification [1]
and the Sainte-Anne Hospital classification [35] when applicable
(Table 1). Most tissue samples were obtained from newly
diagnosed tumors, with the following exceptions: TP9, TP38,
and TP82 (chemotherapy prior surgery) and TP45 (chemo-
radiotherapy prior surgery). Cultured samples were excluded from
the analysis when neuropathological examination showed wide-
spread areas of necrosis, paucity of tumor cells, or signs of per-
operating coagulation. Non-tumoral cerebral samples taken at
distance from a cavernoma and from non-infiltrating tumors were
used as controls. Fifty-five tumor samples were obtained from 52
patients (3 of them having been submitted twice to surgery). The
median age of the cohort was 7.8 years (range, 1.2-15.5). During a
median follow-up of 1.8 years (range, 0.1–3), 11 patients died.
There was no association between age group (above and below
median age) and histopathological subtypes. All patients with high-
grade tumors received post-operative chemotherapy or radiother-
apy, whereas those with low-grade tumors were treated with
surgery alone.
Self-renewal abilities distinguish progenitor-like and
stem-like tumor cells
Cells derived from non-tumoral tissues did not form floating
spheres and did not survive beyond 1.5 months. In contrast,
floating cellular spheres (hence after designed as oncospheres) were
observed in 49/55 tumor cultures (Figure 1 and Figure S2). Only
part of the cultures containing oncospheres exhibited self-renewal
capabilities (Figure 1, left panel). Twelve of the 55 tumors yielded
cells forming spheres that upon dissociation either did not generate
novel spheres or generated spheres in numbers smaller than or
similar to the ones evaluated in the previous passage. In those
cases, sphere formation was likely to result from cell aggregation.
Such a situation was encountered for both low and high malignant
tumors (Figure S2). Importantly, cells forming spheres without self-
renewal properties did not form tumors in vivo (see below).
Self-renewal properties were then assessed through evaluating for
each individual culture the numbers of secondary spheres generated
by dissociated cells at each passage. One self-renewal was scored
when the numbers of secondary spheres doubled, as compared to
the previous passage. Cells with limited self-renewal properties
yielded secondary spheres at least twice but less than 7 times. Cells
with extended self-renewal properties exhibited at least 7 self-
renewals (see the Material and Methods section). We observed a
strong association between the type of self-renewal properties (either
limited like neural progenitors or extended like neural stem cells)
and the histopathological subtypes (P=0.002, chi-square test,
Figure 1, right panel). All medulloblastoma-derived oncospheres
exhibited the limited self-renewal abilities of progenitor-like cells
(Figure 1 and Figure S3). Cells with progenitor-like self-renewing
properties dominated in low-grade gliomas and neuro-glial tumors,
whereas high-grade gliomas yielded essentially cells with extended
self-renewal properties (Figure 1 and Figure S3). Among these
tumor types, isolation of cells with self-renewal properties akin to
neural stem cells was associated with malignant status (P=0.014,
chi-square test, Figure 1). Regardless of tumor entities, the young
age group was associated with self-renewal properties akin to neural
stem cells (P=0.05, chi-square test).
In physiological situations, only neural stem cells and, to a lesser
extent, neural progenitors form colonies in a semi-solid medium or
when cultured under limiting dilutions [14]. Clonal cell frequen-
cies were assayed using these assays on nine cultures of pediatric
tumors. They ranged from 0.07% (for a ganglioglioma culture
containing floating spheres that did not self-renew) to 86% (for an
oligoastrocytoma III culture) (Figure S4). This wide range of
frequency of oncosphere-forming cells was similar to those
reported in previous studies of adult brain tumor TSCs [7,9,25].
High-resolution oligonucleotide array-CGH analysis showed
that cells forming spheres exhibited severe chromosomal aberra-
tions in each of the cultures examined (Figure S5). In addition, we
identified distinct point mutations of the TP53 gene in oncospheres
derived from four tumor samples: TP54 (R248Q), TP59 (R273C),
TP80 (R273H), and TP84 (R158G). Survey of p53 nuclear
immunoreactive signal accumulation, a TP53 mutation surrogate
[36], was performed in a subset of the original tumor panel using
the surgical samples preserved for histo-pathological analysis. The
results showed $50% p53-immunoreactive cells in 7/10 high-
grade gliomas (Table S2), in accordance with reported frequencies
of TP53 mutations in pediatric malignant gliomas [37].
In summary, cells demonstrating ability to form self-renewing
oncospheres were obtained in 37 of the 55 pediatric brain tumors
studied. They were observed in the majority of tumors within each
broad histopathological and grade categories studied. All cultures
containing cells with limited self-renewal properties stopped
proliferating within 5 months on average. Of note, only 30% of
Tumor Stem-Like Cells in Pediatric Brain Tumors
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NAME DIAGNOSIS AGE SEX LOCATION SURGERY
NON TUMORAL TISSUE
TP27 Non tumoral part of a cavernoma 13 M Parietal lobe Resection
TP30S Non tumoral part of a pilocytic astrocytoma 2 M Optical pathway Resection
TP31 Non tumoral lesion 4 F Brainstem Biopsy
TP32S Non tumoral part of a Choroid Plexus papilloma 3 M Posterior fossa Resection
EMBRYONAL TUMORS
TP4 Medulloblastoma 9 M Posterior fossa Resection
TP6 Medulloblastoma 1.3 M Posterior fossa Resection
TP21 Medulloblastoma 6 M Posterior fossa Resection
TP36 Medulloblastoma 13 M Posterior fossa Resection
TP37 Medulloblastoma 7 M Posterior fossa Resection
TP38 Medulloblastoma
1 9 F Posterior fossa Resection
TP22 Atypical Teratoid/Rhabdoid tumor 8 M Parietal lobe Resection
LOW-GRADE GLIAL AND NEURO-GLIAL TUMORS
TP9 Pilocytic Astrocytoma 6 M Intra-lateral ventricle and optical pathway Resection
TP30T Pilocytic Astrocytoma
1 2 M Optical pathway Resection
TP34 Pilocytic Astrocytoma 2 F Optical pathway Resection
TP39 Pilocytic Astrocytoma 13 F Posterior fossa Resection
TP47 Pilocytic Astrocytoma 2 M Posterior fossa Resection
TP53 Pilocytic Astrocytoma 15 M Spinal cord Resection
TP55 Pilocytic Astrocytoma
1 3 F Optical pathway Resection
TP57 Pilocytic Astrocytoma
1 12 M Posterior fossa Resection
TP58 Pilocytic Astrocytoma 2 M Optical pathway Resection
TP73 Pilocytic Astrocytoma
1 6 F Posterior fossa Resection
TP78 Pilocytic Astrocytoma 5 F Hypothalamus Resection
TP79 Pilocytic Astrocytoma 1.5 M Posterior fossa Resection
TP81 Pilocytic Astrocytoma 14 M Intraventricular nodule Resection
TP10 Ganglioglioma 1.8 M Hypothalamus Resection
TP12 Ganglioglioma
1 5 F Cerebellar peduncle Resection
TP14 Ganglioglioma
1 13 F Temporal lobe Resection
TP28 Ganglioglioma 9 M Frontal lobe Resection
TP35 Ganglioglioma 12 F Posterior fossa Resection
TP43 Ganglioglioma anaplasic 13 M Parieto-occipital lobe Resection
TP60 Ganglioglioma 13 M Posterior fossa Resection
TP68 Ganglioglioma 7 M Cerebellar peduncle Resection
TP77 Ganglioglioma or Dysembryoplasic neuroepithelial tumor 11 M Temporal lobe Resection
TP2 Angiocentric NeuroEpithelial Tumor (Oligodendroglioma A) 15 M Temporal lobe Resection
TP11 Angiocentric NeuroEpithelial Tumor 2 M Frontal lobe Resection
TP54 Fibrillary Astrocytoma II (Oligodendroglioma A) 9 M Brainstem Biopsy
TP17 Oligoastrocytoma II (Oligodendroglioma A) 6 F Brainstem Biopsy
EPENDYMOMA
TP8 Ependymoma III 9 M Frontal lobe Resection
TP16 Ependymoma III 5 M Frontal lobe Resection
TP20 Ependymoma III 7 M Posterior fossa Resection
TP45 Ependymoma III 8 M Cerebellar peduncle Resection
TP48 Ependymoma III 13 M Posterior fossa Resection
TP56 Ependymoma III 2 F Posterior fossa Resection
TP62 Ependymoma III 2 M Parietal lobe Resection
TP64 Ependymoma III 2 M Parieto-occipital lobe Resection
TP65 Ependymoma III 11 F Posterior fossa Resection
Tumor Stem-Like Cells in Pediatric Brain Tumors
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(6/19), all derived from grade II-IV gliomas (one astrocytoma II,
two astrocytoma III, two oligoastrocytoma III and one glioblas-
toma), could be maintained beyond 6 months of culture. The
others underwent a proliferation arrest, followed by their
progressive disappearance.
Tumor cells with prolonged self-renewal properties are
associated with poor patient outcome
We evaluated the prognostic factor of patients with self-
renewing tumor cells. For the whole cohort (45 patients for which
clinical information was available) we found a strong statistical
correlation between the dead/alive status of the patient and the
self-renewal properties of the tumor cells (P=0.001, chi-square
test), tumor cells with limited neural progenitor-like self-renewal
properties defining a group of patients with intermediate survival
expectancies (Figure 2). At the time of analysis (November 2010),
only 55% of the patients with a tumor containing ‘‘stem-like tumor
cells’’ were alive, versus 78% and 100% with tumors containing
‘‘progenitor-like tumor cells’’ and no self-renewing cells, respec-
tively. Survival analysis of the whole cohort indicated that tumors
containing ‘‘stem-like tumor cells’’ were associated with a poorer
Figure 1. Self-renewal properties of cell-forming oncospheres
derived from pediatric brain tumors. Left panel. Percent of
tumors yielding cell-forming oncospheres (white bars) and oncospheres
able to self-renew at least twice (dark bars). Right panel. The majority
of high-grade glioma-derived oncospheres exhibited higher self-
renewal properties than oncospheres derived from embryonal tumors,
low-grade glial and neuro-glial tumors or ependymomas. Grey bars:
cultures containing oncospheres devoid of self-renewal properties. Blue
bars: cultures containing oncospheres with limited self-renewal abilities
akin to neural progenitor-like cells. Red bars: cultures containing
oncospheres with extended self-renewal properties akin to neural stem-
like cells.
doi:10.1371/journal.pone.0016375.g001
Figure 2. Association of self-renewal capacities with survival.
Kaplan-Meier curves of the whole cohort show that patients whose
tumor had led to cells having self-renewal properties akin to neural
stem cells had a poorer prognosis compared to those with progenitor-
like properties or those devoid of renewal abilities (P=0.022, log-rank
test). Crosses placed over the curves mark the time of the loss of a
patient (death or last appointment follow-up).
doi:10.1371/journal.pone.0016375.g002
NAME DIAGNOSIS AGE SEX LOCATION SURGERY
TP76 Ependymoma II 10 F Posterior fossa Resection
HIGH-GRADE GLIAL TUMORS
TP13 Astrocytoma III (Oligoastrocytoma A) 10 M Brainstem Biopsy
TP59 Astrocytoma III (Oligoastrocytoma B) 13 M Thalamus Resection
TP80 Astrocytoma III (Infiltrating glioma) 5 F Brainstem Biopsy
TP7 Oligoastrocytoma III (MGNT) 8 M Thalamus Resection
TP25 Oligoastrocytoma III
1 (MGNT) 8 M Thalamus Resection
TP44 Oligoastrocytoma III (MGNT) 10 M Brainstem Biopsy
TP83 Oligoastrocytoma III (Infiltrating glioma) 5 F Brainstem Biopsy
TP84 Oligoastrocytoma III (Oligoastrocytoma B) 9 M Brainstem Biopsy
TP52 Oligodendroglioma III
1 (Oligodendroglioma B) 13 F Intraventricular nodule Resection
TP15 Glioblastoma (MGNT) 5 F Brainstem Biopsy
TP82 Glioblastoma
1 (MGNT) 8 M Thalamus Resection
TP26 Unclassifiable (MGNT) 1.2 M Temporal lobe Resection
The WHO [1] and, when applicable, the Sainte-Anne Hospital classification [35] in parenthesis are indicated.
1Recurrence.
doi:10.1371/journal.pone.0016375.t001
Table 1. Cont.
Tumor Stem-Like Cells in Pediatric Brain Tumors
PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e16375outcome (P=0.013, log-rank test; Figure 2). Although patients
with tumors containing ‘‘progenitor-like cells’’ appeared to
constitute an intermediate group of survival, this group did not
reach statistical significance as compared with either of the other
groups. Multivariate Cox regression analysis in the full cohort
showed that isolation of cancer cells with extended self-renewal
properties from the tumors of the patients were a significant
prognostic marker for survival, independent of age group and
histopathological subtype (95% CI, 0.07 to 0.79; P=0.018).
However, no statistical significance was reached when the analysis
was restricted to the high-grade gliomas subgroup.
Neural stem cell and mesenchymal molecular profiles in
pediatric brain tumor-derived oncospheres
Pediatric glioma self-renewing cells exhibited a neural profile. In
all cultures studied by immunocytochemistry, cell-forming spheres
shared markers with human fetal neural stem cells (Figure 3).
Immunocytochemistry showed that Sox2 and Bmi1, which are
necessary for the normal functioning of both embryonic stem cells
and neural stem cells [39,40], were expressed by a majority of cells
in the low- and high-grade gliomas cultures studied (10/10 and 6/
6 cultures, respectively, Figure 3A, C, and D). Likewise, the neural
stem cell marker Nestin was detected in the majority of the cells in
all cultures examined (12/12 cultures, Figure 3A, E, and F). In
addition, we observed cells immunoreactive for the stage-specific
embryonic antigen 4 (SSEA4) a marker of embryonic stem cells
and of the early neuro-epithelium [38] in seven of the ten cultures
we assayed and that were derived from low- and high-grade glial
tumors (Figure 3A–B). In accordance with the well-known co-
existence of stem cells with their progeny at different stages of
differentiation in neural stem cell as well as TSC cultures growing
under the form of floating spheres [6,41], we observed cells
immunoreactive for the neural progenitor markers BLBP/FABP7
and Olig2 in oncospheres of the glial tumors examined (12/12 and
5/5 cultures, respectively, Figure 3A, G, H). Immunocytochem-
istry additionally showed a widespread and robust expression of
Vimentin (Figure 3A and Figure S6a), an intermediate filament
that, like Nestin, is expressed by neural stem cells and neural
progenitors in the developing CNS. Of the markers of neuronal
lineage, only b3-tubulin, which is normally restricted to neuro-
blasts and immature neurons in the normal CNS and is known to
be expressed by tumoral glial cells in adults [47], was observed in
Figure 3. Self-renewing cell-forming spheres derived from both low-grade and high-grade gliomas have a neural stem cell profile
combined with neural progenitor markers indicative of both pro-neuronal and pro-glial potencies. A. Summary of the
immunocytochemical analysis of glioma-derived cells forming self-renewing oncospheres. nd: not determined. +: immunoreactive cells. -: no
immunoreactive cells. See text for further details. B-K. Examples of immunoreactive cells. B. SSEA4-immunoreactive cells in floating spheres derived
from an astrocytoma II. C. Sox2-immunoreactive cells derived from an oligoastrocytoma III. D. Bmi1-immunoreactive cells derived from an
astrocytoma III. E. Nestin-immunoreactive cells derived from an astrocytoma II. F. Nestin-immunoreactive cells derived from an ependymoma. G.
BLBP/FABP7-immunoreactive cells derived from an ependymoma III. H. Olig2-immunoreactive cells derived from an astrocytoma III. I. b3-tubulin-
immunoreactive cell-forming spheres derived from a pilocytic astrocytoma J. GFAP-immunoreactive cells derived from an oligoastrocytoma III. K.
Example of CNPase-immunoreactive cells in an astrocytoma II culture. Bar=15 mm in B and K, 20 mm in C, H and J; 25 mm in D, E; 100 mm in F, G, and I.
In panels E, H, J and K, the floating oncospheres were smeared onto a glass slide prior to being submitted to the immunocytochemical procedure. B-
K, Hemalun or DAPI counterstaining.
doi:10.1371/journal.pone.0016375.g003
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Figure 3A, and I). Conversely, cells expressing NeuN, a marker of
mature neurons, were exceptionally observed (rare cells in 3/7
cultures, Figure 3A and Figure S6b). Cells expressing GFAP,
which is normally observed in vivo in astrocytes and in neural
progenitors and neural stem cells of the developing human brain
[48], were abundant (.50% of the cells) in all our cultures (12/12
cultures, Figure 3A, and J). Surprisingly, the enzyme CNPase that
is normally produced by myelinating oligodendrocytes, was
expressed by the majority of cells in the six cultures examined
(Figure 3A, and K).
We completed this study by determining in one low-grade and
three high-grade glioma-derived cultures the expression of the
neural stem cell markers Prominin/CD133 and SSEA1/CD15 as
well as the levels of embryonal/neural stem cells and mesenchymal
markers as compared to neural stem cells. FACS revealed that a
majority of the cells expressed Prominin/CD133, SSEA1/CD15,
or both proteins in the four cultures (Figure 4A). Comparative
profiling of tumor-derived oncospheres and neural stem cells with
regards to markers of embryonic stem cells, neural stem cells,
neural progenitors, and mesenchymal cells was achieved using
qPCR. A mesenchymal signature has recently been shown to be
associated with the expression of several markers of neural stem
cells in adult glioblastomas TSCs [49]. Transcripts of the
embryonic stem cell markers Oct4, Nanog, and - at low levels -
Klf4 were detected in the four tumor cultures examined (one
astrocytoma II, two astrocytoma III and one oligoastrocytoma III
that yielded cell-forming spheres with extended self-renewal
properties, Figure 4B). Surprisingly, three of them exhibited
enhanced Oct4 and Nanog transcript levels as compared to both
control tissues and fetal neural stem cells (Figure 4B). Enhanced
levels of transcripts encoding Sox2, Musashi 1, Nestin and
Vimentin were observed in the glioma cultures assayed and in
neural stem cells as compared to adult cortical tissues (Figure 4B).
We also observed expression of transcripts encoding the neural
progenitor marker BLBP/FABP7 in neural stem cells and in
glioma-derived cell spheres (Figure 4B). Enhanced levels of
Achaete-scute complex Homolog 1 (ASCL1) and Doublecortin
(DCX) transcripts, markers of neural progenitors engaged in the
early steps of neuronal differentiation [42,43], were observed in
human fetal neural stem cells and all glioma cell cultures examined
as compared to adult cortical tissues (Figure 4B). In contrast,
increased transcript levels of hyaluronan/CD44, which is normally
expressed by astrocyte progenitors [44] and frequently overex-
pressed in TSCs derived from solid tumors (including gliomas)
[45], were observed in all the tumor cultures assayed but not in the
Figure 4. Neural stem cell and mesenchymal molecular profiles of pediatric brain tumor-derived oncospheres. A. Fluorocytometric
analysis of the expression of the neural stem cell markers CD15 and CD133 by cells derived from low- (TP54) and high-grade gliomas (TP59, 80, and
84). B. Comparative qPCR analysis of cell lineage marker expression in different pediatric glioma-derived cells (TP) and human fetal neural stem cells
(NSC). Results are presented relative to the mean transcript levels measured in controls (adult human biopsies of cortices from epileptic patients, CX1,
CX5). Astrocytoma II-derived oncospheres (TP54), astrocytoma III-derived oncospheres (TP59, TP80), oligoastrocytoma III-derived oncospheres (TP84).
Musashi 1 (MSI1), Nestin (NES), Vimentin (VIM), brain lipid binding protein (FABP7/BLBP), Doublecortin (DCX). C. Altered transcript levels of several
genes normally expressed in mesenchymal cells distinguish pediatric glioma-derived cultures (TP) from neural stem cells (NSC).
doi:10.1371/journal.pone.0016375.g004
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(Figure 4B). Conversely, NKX2.2 expression, which is normally
present in neural progenitors engaged in the early steps of
oligodendroglial differentiation [46], was down-regulated except in
TP59, one of the two astrocytoma III cultures included in this
assay (Figure 4B). We finally observed enhanced transcript levels of
several genes known to play crucial roles in the adoption of a
mesenchymal phenotype [50] in all the cultures we tested, as
compared to both control tissues and fetal neural stem cells
(Figure 4C).
Taken together, these results show that despite an extensive
diversity of molecular markers, cell-forming spheres derived from
both low-grade and high-grade gliomas have a common neural
stem cell profile combined with neural progenitor markers
indicative of both pro-neuronal and pro-glial potencies. This
molecular profile comprises elements known to control mesen-
chymal transitions in the low- and high-grade glioma cultures we
sampled.
In vivo formation of highly infiltrative tumors by pediatric
glioma-derived oncospheres
To determine their tumor-initiating properties, cell-forming
spheres with self-renewing ability derived from three cultures
(TP54, TP80, TP82) were grafted into the brains of nude or NSG
mice, which were sacrificed 3.5 to 6 months post-graft. In the three
mice grafted with TP54-derived cells, tumor cells were observed
throughout both hemispheres (Figure 5A). As in the original
patient tumor (an infiltrating brainstem glioma), numerous cells
were disseminated, were EGFR-immunoreactive (compare
Figure 5B with 5C), and had abnormal nuclei with p53-
immunoreactivity (Figure 5D and E). Similarly, grafts of TP80-
and TP82-derived cells resulted in tumor formation (Figure 6).
Among the cultures containing oncospheres that did not self-
renew, one (TP77) yielded a numbers of spheres sufficient to allow
determining their tumor-initiating properties in vivo. Grafting of
TP77-derived oncospheres in the brain of immunodeficient mice
resulted only in a modest cell accumulation at the injection site
(Figure 6A), showing that these cells devoid of self-renewal
properties in vitro lacked also tumor-initiating properties in vivo.
Together, these results indicate that the tumor cells with long-
term self-renewing capacities we engrafted in mouse brains
resulted in the in vivo development of tumors that recapitulated
the histological and molecular profile of the original human tumor.
Pediatric glioma-derived oncospheres are resistant to
genotoxic stress
According to the TSC hypothesis, tumor recurrence results
from TSC resistance to current therapeutics. The radio- and
chemosensitivity of cell-forming spheres derived from pediatric
gliomas was evaluated using irradiation and the DNA-alkylating
agent temozolomide on four glioma cultures of TSC with long-
term self renewing capacities (two astrocytomas III, TP59 and
TP80, and two oligoastrocytomas III, TP83 and TP84) and on
human fetal brain-derived neural stem cells used for comparison.
Metabolic activity, taken as a survival index, was evaluated one
week post-irradiation or after exposure to a high concentration of
temozolomide. As depicted in Figure 7, TSC derived from
pediatric gliomas survived significantly better than neural stem
cells after both treatments (Student-Newman-Keuls test,
p,0.001).
Figure 5. Tumor formation by cells with stem-like properties
derived from pediatric gliomas. A. Example of tumor formation by
cells derived from an astrocytoma II culture 6 months after grafting into
the right striatum of nude mice. The grafted cells were identified using
an antibody specific to the human form of Vimentin. As in the original
patient tumor (B), the cells that composed the mouse tumors expressed
EGFR (C) and exhibited p53-immunolabeling (D). Hemalun counter-
staining. Bars=110 mmi nA ,1 0mm in B, C and D.
doi:10.1371/journal.pone.0016375.g005
Figure 6. Tumor initiating properties of glioma-derived
oncospheres with and without self-renewal abilities. A. Grafting
of cell forming spheres derived from a ganglioglioma (TP77), which
lacked self-renewal ability resulted in small accumulation of cells
(arrows) but not in tumor formation. B–D. In vivo tumor formation by
tumor cells with stem-like properties derived from pediatric gliomas. B.
Two out of five mice grafted with cells derived from an astrocytoma III
(TP80) exhibited a robust development of tumor cells, which
reproduced the appearance of the patient original tumor, as observed
using Vimentin-immunolabeling. C–D. The histological aspect of the
mouse tumor (C) was comparable to that of the patient original tumor
(D). E–F. A large, infiltrating tumor was observed 6 months after
grafting into the right striatum in one of the three NSG mice grafted
with glioblastoma-derived cells (TP82). Immunolabeling with an
antibody that recognized the human but not the rodent form of
Nestin (E) revealed cells endowed with an elongated, bipolar
morphology similar to that observed in the patient tumor (F). C and
F, hemalun/phloxin counterstaining. A, B, D, E, hemalun counterstain-
ing. Bar=100 mm in A, 250 mmi nB ,2 0mm in C and D, 10 mm in E and F.
doi:10.1371/journal.pone.0016375.g006
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This study provides evidence that tumor cells expressing
markers and self-renewal properties of neural progenitors or
neural stem cells can be isolated, and cultured from most pediatric
brain tumors regardless of subtype or grade of malignancy.
Further analysis of one low-grade and three high-grade glioma
cultures showed that the cells we isolated expressed a complex
molecular profile that combined mesenchymal and neural
elements, suggesting a high potential of plasticity. Testing in vivo
tumorigenicity, we verified that non self-renewing cells did not
form tumors when engrafted in immunodeficient mice brains
whereas the three long-term self-renewing ones we tested
generated tumors respecting the histological and molecular profile
of the original human lesion. Of note, as their adult counterparts
[4,5], the four children gliomas-derived TSC tested here resisted
to chemo- or radiotherapy.
Although cell-forming self-renewing spheres isolated in this
study did not share a unique molecular signature, they all
presented a molecular profile highly similar to that expected for
neural progenitors and/or neural stem cells [40]. This immature
neural profile was associated in the four TSCs cultures we tested
with high-transcript levels of molecules normally present in
mesenchymal cells including CHI3L1/YKL40, which is also
known as a marker of adult glioblastoma aggressiveness [51]. This
observation echoes those recently reported in adult glioma tissues
[52] and in adult glioblastoma-derived TSCs [49,53], and lends
credence to the view that brain TSCs could be characterized by
the unique association of a neural stem cell profile and of a
mesenchymal profile essential for maintaining the tumor initiating
properties of the cells [49]. Epithelial to mesenchymal transition is
a well-known event, which presides on epithelial cancer metastasis
[50], and the most aggressive forms of adult gliomas cluster with a
mesenchymal signature [52]. Most importantly, sharing of a
common molecular profile by cells obtained from pediatric and
adult tissues, and from different gliomas subtypes with different
genomic alterations reinforces the idea that glioma cancer cells
with stem properties play crucial roles in glioma development.
Our observation that tumor cells with self-renewal properties
and markers of neural progenitors and neural stem cells can be
isolated from a majority of pediatric brain tumors favors our initial
hypothesis that TSCs are a common component of brain tumors.
Our success in derivation of self-renewing oncospheres from
pediatric high-grade brain tumors is comparable with or above the
50% average success rate reported to date on adult high-grade
gliomas using the neurosphere assay [7,9,11,13,54,55]. During the
redaction of the present work, a study of 56 pediatric tumors
described the obtaining of oncospheres passageable three times
from 50% high-grade glial tumors (high-grade gliomas and
anaplasic ependymomas), and 20% pilocytic astrocytomas [56],
compared to 85% and 61% observed here for pediatric tumors of
the same histological sub-types. Lack of self-renewing oncospheres
in a minority of the surgical samples cultures may result from
either absence of such cell types in the tumors or from their
requirement of specific growth conditions. The higher yield of self-
renewing oncospheres we observed within a given tumor category,
when compared to Panoysan and colleagues [56], was especially
marked for low-grade neoplasms. This observation suggests that
the ability to derive cells with properties akin to neural progenitors
or neural stem cells from a given tumor could be more dependent
on the absolute numbers of cells endowed with progenitor or stem
properties within the cultured tumor sample, than on the
optimization of culture conditions for each histological tumor
sub-type. Further experiments are necessary to address this issue.
Our analysis over the whole tumor cohort showed a correlated
segregation into three distinct sub-groups between survival
expectancy and the type of self-renewing properties of the cancer
cells, independent of age group and histopathological type of the
tumor. The predictability of this correlation for individual patients
must be moderated according to the finding of tumor cells with
limited or extended self-renewing properties in low-grade tumors
from patients that remained clinically stable without any post-
surgical treatment, and the fact that we obtained such cells from a
large majority of tumors within all categories examined. However,
distinction of an intermediate survival group formed by tumor cells
with limited self-renewal properties indicates that the degree of
immaturity of these cells may provide a pertinent novel model for
the stratification of pediatric brain tumor prognosis. The most
intriguing result of our study is the finding of tumor cells with
properties akin to neural progenitors or neural stem cells in most of
the tumors examined. Although the frequency of TSCs derivation
was higher in high-grade pediatric tumor, our data indicate that in
children such cells were not the monopoly of the most malignant
form of glial tumors contrary to what can be inferred from the
studies on adult brain tumors [6–11,13]. This could suggest that
cells with stem cell-like or progenitor-like properties are more
Figure 7. Resistance of pediatric high-grade glioma-derived tumor stem-like cells to irradiation (A) and temozolomide (B) compared
to human fetal neural stem cells (NSC). A: astrocytoma. OA: oligoastrocytoma. Data represent the mean 6 s.d. (n=3). Student-Newman-Keuls
test, *: p,0.001 as compared to the respective controls. #:p ,0.001 as compared to irradiated NSC in (A) or temozolomide-treated NSC in (B).
doi:10.1371/journal.pone.0016375.g007
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tumors. Consequently, TSCs could be an essential driving force of
pediatric brain tumors and a dispensable element of adult ones.
Alternatively, the fact that such cells were not systematically found
in all tumors within a given category, opens the possibility that
they are not present at all time-points of the tumor development.
The exceptional plasticity of normal somatic cells, exemplified by
the ability of glial progenitors [57], and the ability of mature glial
cells [58,59] to be converted into stem-like cells in response to
defined environmental conditions could suggest that brain cancer
cells can acquire properties of progenitor cells or of stem cells in
response to permissive environmental pressure. Such a possibility
would imply that therapeutic anti-cancer strategies should take cell
plasticity into account.
Supporting Information
Figure S1 Isolation and characterization of neural stem
cells from human fetal brain. All studies with human tissue
were performed under Ethical Approval from the University Paris-
Descartes internal review board using tissue donated with
informed consent after elective termination of pregnancy. Human
fetal brain at embryonic day 50-55 (Carnegie stage 19-22) were
carefully dissected and mechanically dissociated into single cell
suspensions. Primary cells were cultured under the form of floating
spheres in NeuroCultH NSC Basal Medium supplemented with
NeuroCultH Proliferation Supplements (StemCell Technologies),
human EGF 20 ng/mL, human b-FGF 10 ng/mL (AbCys) and
Heparin 20 ng/mL (Sigma-Aldrich) final. Two primary cultures of
neural stem cells (NSC24 and NSC25) were established from two
distinct fetuses, and expanded with a passage every two weeks. No
culture crisis, spontaneous differentiation or abnormal genetic
derivation as assessed by CGH array was detected over one year of
continuous culture. Clonal properties were determined after 4
months of culture (passage 12) by manual deposition of 1 cell/
100 mL into non-coated 96-well plates. Fifty mL of medium was
added every two weeks during two months. 5.9%61.2 of CSN24
cells, and 4.5%61.6 of CSN25 cells yielded spheres in these
conditions. Immunocytochemical analysis showed that most cells
expressed the NSC markers Sox2, Bmi1 and Nestin, while no cell
immunoreactive for Synaptophysin, phosphorylated neurofila-
ments, and NeuN was observed. Left panel: Immunocytochem-
ical labeling showing protein expression of the NSC markers Bmi-
1, Sox2 (brown nuclei staining) and Nestin (brown cytoplasm
staining). Hemalun counterstaining. Scale bar=25 mm. Right
panel: Entire genome profile of NSC using HumanCytoSNP-12
Beadship. These graphs represent the allelic copy ratio in terms of
B allele frequency (diagnosing genetic aberrations) and the log2
ratio of the fluorescence intensities along each chromosome noted
log R ratio (monitoring physical aberrations). Copy number was
normal (CN=2), no duplication or deletion were detected.
(TIF)
Figure S2 Distinct behavior in serum-free medium
cultures of cells derived from low-grade gliomas and
neuro-glial tumors as compared with other pediatric
brain tumors-derived cells. a. As expected, cells growing
under the form of floating oncospheres were observed in cultures
of medulloblastoma (MDB). b–n. Oncospheres were observed in
cultures derived from both low- and high-grade brain tumors.
Cultures of pilocytic astrocytomas and gangliogliomas were
characterized with anchored clusters of round shaped cells from
which cells with long extensions departed. Floating cellular spheres
budded from the attached cell networks. Over time, cells could
spread between the clusters, forming loosely dense networks. Only
the floating spheres could be expanded. All attempts to amplify the
cell networks through re-seeding were unsuccessful. b–c. Cultures
of pilocytic astrocytomas formed cell networks anchored to the
culture vials (b) prior to develop under the form of oncospheres (c)
that coexisted with anchored cells. d–e. Ganglioglioma derived
cells formed anchored cell networks developing from cellular
aggregates (d) prior to yield oncospheres (e). Among the low-grade
gliomas cultured, only the grade II astrocytoma-derived cells
developed straightforwardly under the form of floating spheres. f–
g. All ependymoma cultures contained floating spheres. Ependy-
moma-derived cells exhibited various growth aspects from one
sample to another. They grew either under the form of anchored
cells prior to yield oncospheres (f) or directly under the form of
free-floating oncospheres (g). h–n. Floating spheres were observed
in all high-grade gliomas cultures within two weeks post-seeding,
and dominated over anchored cells. h–j. Cells derived from
astrocytomas grew under the form of oncospheres (h and j)
coexisting with cells and cellular aggregates loosely anchored to
the culture vial (i). k. Oligoastrocytoma-derived cells developed as
oncospheres. l–m. Glioblastoma-derived cells developed under
the form of patches of anchored-cells, which yielded oncospheres.
n. Example of oncospheres derived from a tumor corresponding
to a MGNT according to Sainte-Anne hospital classification.
(TIF)
Figure S3 Self-renewal properties of oncospheres de-
rived from each tumor category. The absolute numbers of
tumors are indicated on each bar. Grey bars: tumor-derived
cultures containing oncospheres devoid of self-renewal properties.
Blue bars: tumor-derived cultures containing oncospheres with
limited self-renewal (SR) ability akin to neural progenitor-like cells
(2#SR#7). Red bars: tumor-derived cultures containing onco-
spheres with extended self-renewal property akin to neural stem-
like cells (SR.7). In a, the tumors are categorized along the WHO
classification and in b along the Sainte-Anne hospital classifica-
tion.
(TIF)
Figure S4 Clonal properties of cell-forming spheres (a).
b-c. Example of colony obtained in methylcellulose medium for a
ganglioglioma culture (b) and an astrocytoma culture (c).
(TIF)
Figure S5 Examples of cytogenomic profiles of onco-
spheres derived from a paediatric astrocytoma II (a)
and III (b). Aberrations were obtained with the ADM2
algorithm and filtering options of a minimum of 3 probes and
abs (log 2 ratio)=0.4. Profiles of segmental chromosomal copy
number alterations (log 2 ratio.0.4) are represented with green
(losses) and red (gains) lines.
(TIF)
Figure S6 Examples of vimentin, and neuN expression
in oncospheres derived from an oligoastrocytoma III (a)
and a fibrillary astrocytoma II (b). Bar=20 mmi na ,1 0mm
in b.
(TIF)
Table S1 Antibodies used for immunocyto- (ICC),
immunohistochemical (IHC), and flow cytometry (FACS)
analyses. All incubations for ICC and IHC were performed for
1 hour at room temperature unless otherwise indicated. Cells
growing under the form of cellular spheres were collected,
mechanically spread onto Superfrost glass slides (Dutscher,
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Cells growing in an anchored manner were directly treated with
2–4% paraformaldehyde in PBS for 10 min. Eight mm-thick
sections were prepared from paraffin-embedded mouse brains,
and from initial tumor samples, and 30 mm-thick free-floating
sections from frozen mice brains. For FACS, cells were labelled
with anti CD133-PE and anti CD15-FITC antibodies in a ratio of
5 mL of each antibody per 10
6 cells in a total volume of 100 mL for
30 minutes at 4uC. Isotype controls coupled to the same
fluorophores were used as control antibodies. Data acquisition
was performed on FACScalibur (BD Biosciences) and analysed
using FlowJo software (Tree Star Inc.).
(DOC)
Table S2 Immunohistochemical detection of p53 in a
subset of the original patient tumor panel.
(DOC)
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